This inventor holds 1 USPTO granted patent. Top assignees: The General Hospital Corporation, The State University of New York. Active years: 1994.
Company Filing History:
1 out of 3,071 
1 out of 2,044 
Years Active: 1994
Title: The Innovative Contributions of Desire Collen
Introduction
Desire Collen is a notable inventor based in Winksele, Belgium. He has made significant contributions to the field of medical treatments, particularly in addressing myocardial infarction. His innovative approach has the potential to change the way this critical condition is treated.
Latest Patents
Desire Collen holds a patent for a method of treatment for myocardial infarction. This invention involves administering a hapten-binding molecule that prevents the reformation of fibrin-platelet clots, along with a thrombolytic agent that can dissolve these clots or inhibit their formation. The therapy aims to increase clot lysis while minimizing fibrinogen breakdown and preventing the reocclusion of the affected coronary artery. Remarkably, this treatment can achieve its goals even without heparin and with lower concentrations of the thrombolytic agent compared to other therapies.
Career Highlights
Throughout his career, Desire Collen has worked with prestigious organizations, including The General Hospital Corporation and The State University of New York. His experience in these institutions has contributed to his expertise in medical innovations and treatments.
Collaborations
Desire Collen has collaborated with esteemed colleagues such as Herman K Gold and Barry S Coller. These partnerships have likely enriched his research and development efforts in the medical field.
Conclusion
Desire Collen's work in developing a novel treatment for myocardial infarction showcases his innovative spirit and dedication to improving medical therapies. His contributions have the potential to significantly impact patient care and treatment outcomes.